key: cord-0012001-svhh57v4 authors: nan title: 合并肢端缺血表现的危重型新型冠状病毒肺炎七例临床分析 date: 2020-04-03 journal: Zhonghua Xue Ye Xue Za Zhi DOI: 10.3760/cma.j.issn.0253-2727.2020.0006 sha: a222ae8f247d0914ada14921292787d23a5531ab doc_id: 12001 cord_uid: svhh57v4 OBJECTIVE: To investigate the clinical and coagulation characteristics in patients with critical Coronavirus disease 2019 (COVID-19) and acro-ischemia. METHODS: The retrospective study included 7 critical COVID-19 patients with acro-ischemia in an intensive care unit (ICU) in Wuhan, from Feb 4 to Feb 15, 2020. The clinical and laboratory data before and during the ICU stay were analyzed. RESULTS: The median age of 7 patients was 59 years and 4 of them were men. Three patients were associated with underlying comorbidities. Fever, cough, dyspnea and diarrhea were common clinical symptoms. All patients had acro-ischemia presentations including finger/toe cyanosis, skin bulla and dry gangrene. D-dimer, fibrinogen and fibrinogen degradation product (FDP) were significantly elevated in most patients. Prothrombin time was prolonged in 4 patients. D-dimer and FDP levels progressively elevated consistent with COVID-2019 exacerbation. Four patients were diagnosed with disseminated intravascular coagulation (DIC). Low molecular weight heparin (LMWH) was administrated in 6 patients, which reduced D-dimer and FDP rather than improved clinical symptoms. Five patients died finally and the median time from acro-ischemia to death was 12 days. CONCLUSION: Coagulation parameters should be monitored closely in critical COVID-2019 patients. The timing and protocol of anticoagulation therapy are still under investigation based on more clinical data. 量血管活性药物 (去甲肾上腺素<0.3 μg·kg -1 ·min -1 ) , 同期动脉血气分析示乳酸含量均不高 (<2.0 mmol/L) , 无躯干及膝关节等部位皮肤花斑等。 所有患者均接受人丙种球蛋白 (5~20 g/d×5 d) 及大剂量维生素 C (100 mg·kg -1 ·min -1 ) , 其中 5 例患 者 于 发 病 初 期 接 受 糖 皮 质 激 素(甲 泼 尼 龙 40~ 80 mg/d, 3~5 d) 治疗。6 例患者接受了低分子肝素 抗凝治疗, 剂量为 100 IU/kg, 每日 2 次, 抗凝中位治 疗时间为 8 (3~14) d, 抗凝治疗中未出现消化道出 血、 颅内出血、 气道出血、 深部血肿等严重出血事 件。末次随访日期为 3 月 2 日, 5 例患者死亡, 起病 至死亡的中位时间为 26(25~36)d, 肢端缺血至死 亡的中位时间为 12 (7~16) d, 死亡原因均为重度低 氧血症及呼吸性酸中毒导致的循环衰竭。2 例存活 患者仍在 ICU 治疗, 肺部情况未见好转, 未脱离机 械通气。例 3 足底缺血有所改善, 但例 2 下肢缺血 进行性加重, 已出现肢端坏疽。 二、 实验室检查 1. 入院时: 所有患者均存在不同程度淋巴细胞 减 少[ (0.37~1.09)× 10 9 /L) ], 2 例 患 者 WBC 升 高 [ (11.05~13.08) ×10 9 /L] , 1 例患者轻度贫血。所有 患者 ALT、 血肌酐水平均在正常范围, 低白蛋白血 症 及 LDH 升 高 比 例 为 85.7% , 心 肌 肌 钙 蛋 白 I (cTnI) 升高比例为 42.9%。所有患者均存在超敏 C 反应蛋白(hsCRP)升高(47~133 mg/L, 正常参考 值<1 mg/L) 。所有患者入院时 PLT 均在正常范围 [ (136~350)×10 9 /L], D-二 聚 体 水 平(纤 维 蛋 白 原等 量 单 位 , FEU)1.25~21.00 μ g/ml (正 常 参 考 值<0.50 μg/ml) , 中位数为 7.13 μg/ml。83.3% (5/6) 的患者出现纤维蛋白降解产物(FDP)升高(9.6~ 150.0 μg/ml, 正常参考值<5 μg/ml) 。85.7%的患者 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J] Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J] 试行第七 版) [Z] . 2020 年 3 月, 国卫办公函 [2020] 184 号 Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS [J] Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus[J] Clinical Characteristics of Coronavirus Disease 2019 in China[J] Clinical features of patients infected with 2019 novel coronavirus in Wuhan Role of Infectious Diseases in the Antiphospholipid Syndrome(Including Its Catastrophic Variant) [J] Catastrophic antiphospholipid syndrome(CAPS)induced by influenza A virus subtype H1N1[J] Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[pub-lished online ahead of print